Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine

This page shows the latest Editas Medicine news and features for those working in and with pharma, biotech and healthcare.

Trial dents confidence in Sangamo’s gene-editing tech

Trial dents confidence in Sangamo’s gene-editing tech

Companies developing other gene-editing technologies, such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine, also saw their shares close down, suggesting a knee-jerk reaction in the sell-off.

Latest news

  • Editas CEO exits the CRISPR firm ahead of first clinical trial Editas CEO exits the CRISPR firm ahead of first clinical trial

    Shares in company and competitors sink. Gene-editing specialist Editas Medicine will have to start its first CRISPR clinical trial without the direction of president and CEO Katrine Bosley, who has ... The multiple departures and the timing of Bosley’s

  • Sangamo’s first gene-editing trial doesn’t convince investors Sangamo’s first gene-editing trial doesn’t convince investors

    Principal investigator Joseph Muenzer of the University of North Carolina (UNC) School of Medicine in Chapel Hill described those reductions are encouraging, saying: “We hope to understand the clinical relevance of ... But companies developing other

  • Allergan builds on gene editing deal Allergan builds on gene editing deal

    The Allergan team is excited to work with colleagues at Editas Medicine to develop EDIT-101 and potentially deliver a transformative medicine for LCA10 patients.". ... These developments have caused the shares of leaders in the field, CRISPR Therapeutics,

  • Bayer forms JV with gene editing firm CRISPR Bayer forms JV with gene editing firm CRISPR

    CRISPR was formed by a team led by Emmanuelle Charpentier, who was awarded the Janssen Award for Biomedical Research last year - along with Jennifer Doudna of Editas Medicine - for the discovery

  • Vertex forges ties with gene editing firm CRISPR Therapeutics Vertex forges ties with gene editing firm CRISPR Therapeutics

    CRISPR Therapeutics was formed by a team led by Emmanuelle Charpentier, who was awarded the Janssen Award for Biomedical Research last year - along with Jennifer Doudna of Editas Medicine - for the ... Editas - backed by Google and Bill Gates - has yet

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    In November, the US Food and Drug Administration (FDA) approved Editas Medicine’s Investigational New Drug (IND) application for a phase 1/2 trial of its Allergan-partnered CRISPR drug ... Editas, and the failure of Sangamo Therapeutics’ rival

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    EDIT-101 is an experimental CRISPR genome-editing medicine that is currently being investigated by Editas for the treatment of Leber congenital amaurosis 10 (LCA10), an inherited eye condition. ... Editas Medicine and partner Allergan plan to initiate a

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Deal Watch May 2016 Deal Watch May 2016

    This follows the $94m IPO of Editas Medicine in February this year.

  • Deal Watch October 2015 Deal Watch October 2015

    companies. Other biotechs exploiting the CRISPR/Cas-9 technology for the development of therapeutics include Editas Medicine, Intellia Therapeutics and Caribou Biosciences; both Novartis and AstraZeneca have already developed collaborations in

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Editas Medicine names James Mullen as chairman Editas Medicine names James Mullen as chairman

    He has previously served as CEO of Patheon. Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors. ... Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned

  • Editas Medicine adds to its board of directors Editas Medicine adds to its board of directors

    Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board's audit committee. ... She said: “I am honoured to join Editas Medicine’s board of directors. “

  • Editas Medicine adds to board of directors Editas Medicine adds to board of directors

    Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... Katrine Bosley, Editas Medicine's president and chief executive officer, said: “I am

More from appointments
Approximately 3 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics